sotrovimab (Xevudy; VIR-7831) - versus control - for COVID 19 outpatients pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.25 [0.01, 5.55]< 10%1 study (1/-)80.7 %NAnot evaluable crucial-
deaths 0.25 [0.01, 5.55]< 10%1 study (1/-)80.7 %NAnot evaluable crucial-
hospitalization or death 0.21 [0.09, 0.49]< 10%1 study (1/-)100.0 %NAnot evaluable crucial-
clinical deterioration 0.24 [0.10, 0.56]< 10%1 study (1/-)100.0 %NAnot evaluable important-
hospitalization 0.20 [0.08, 0.48]< 10%1 study (1/-)100.0 %NAnot evaluable important-

safety endpoints 00

adverse events 0.91 [0.68, 1.22]< 10%1 study (1/-)73.0 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.